Clinical Trials Logo
  1. Home
  2. Type I Hypersensitivity
  3. NCT00133159

Different Doses of Tyrosine Adsorbed Grass Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Grass Pollen

Type I Hypersensitivity Clinical Trial

Official title:
A Double-Blind Phase IIb Study to Evaluate the Safety and Efficacy of Different Doses of Tyrosine Adsorbed Grass/Rye Pollen Allergoid With MPL in Patients Sensitized to Grass and Rye Pollen

Clinical Trial Summary

Allergen-specific immunotherapy (SIT), the administration of gradually increasing quantities of an allergen extract to an allergic patient, is a curative approach which directly treats the underlying allergic disease. GrassMATAMPL has been developed to provide pre-seasonal specific immunotherapy for patients with an allergy to grass pollen (hay fever). The purpose of this double-blind Phase IIb study is to assess the tolerability and immunogenicity of different doses of GrassMATAMPL in volunteers allergic to grasses and rye pollen.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00133159
Study type Interventional
Source Allergy Therapeutics
Contact
Status Completed
Phase Phase 2
Start date September 12, 2005
Completion date November 8, 2005
View Details
See also
  Status Clinical Trial Phase
Completed NCT00133146 - Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Grass Pollen Allergy Vaccine Phase 2
Terminated NCT00387478 - Investigation of Efficacy and Safety of Tree MATAMPL,Tree MATA, and Placebo in Patients With Birch-Induced Seasonal Allergic Rhinitis Phase 2
Completed NCT00414141 - Efficacy and Safety/Tolerability of Grass MATA MPL Phase 3
Completed NCT00258635 - Investigation of Safety+Efficacy of Different Doses of RagweedMATAMPL;Assessment of Residual Allergenicity Using Skin Prick Test Phase 2
Completed NCT00325338 - Follow-up Investigation of Efficacy of Ragweed MATAMPL,and Placebo in Patients With Ragweed-induced Seasonal Allergic Rhinitis Phase 2
Withdrawn NCT00109759 - Evaluation of Safety and Tolerability of Tyrosine Adsorbed Ragweed Pollen Allergoid With MPL (Monophosphoryl Lipid A) Phase 1
Completed NCT00110786 - Investigation of Efficacy and Safety of Ragweed MATAMPL, Pollinex-R and Placebo in Patients With Ragweed Allergy Phase 2
Completed NCT00423787 - Efficacy and Safety/Tolerability of Ragweed MATA MPL Phase 3
Completed NCT00104377 - Induction of Immunogenicity With Different Doses of Grass MATA in Subjects Allergic to Grass and Rye Pollen Phase 2
Completed NCT00104390 - Assessment of Residual Allergenicity of Grass/Rye Pollen Allergoid Using Skin Prick Testing Phase 1
Completed NCT00116285 - Assessment of Residual Allergenicity of Ragweed Pollen Allergoid With Monophosphoryl Lipid A (MPL) Using Skin Prick Testing Phase 1
Completed NCT00118612 - Different Doses of Tyrosine Adsorbed Tree Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Tree Pollen Phase 2
Completed NCT00113750 - Induction of Immunogenicity With Different Doses of TreeMATA in Subjects Allergic to Tree Pollen Phase 2
Completed NCT00118625 - Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Tree Pollen Allergy Vaccine Phase 2
Completed NCT00241410 - Safety, Immunological Effect and Efficacy of the Combined Application of MPL and Grass Pollen Allergen Phase 1
Completed NCT00107705 - Assessment of Residual Allergenicity of Tree (Birch, Hazel, and Alder) Pollen Allergoid Using Skin Prick Testing Phase 1